Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RZLT |
---|---|---|
09:32 ET | 418 | 1.86 |
09:34 ET | 5947 | 1.56 |
09:36 ET | 1200 | 1.7 |
09:48 ET | 400 | 1.82 |
10:06 ET | 100 | 1.9 |
10:08 ET | 200 | 1.85 |
10:12 ET | 600 | 1.86 |
10:28 ET | 891 | 1.89 |
10:57 ET | 100 | 1.93 |
11:42 ET | 140 | 1.92 |
11:47 ET | 100 | 1.89 |
11:51 ET | 100 | 1.89 |
12:00 ET | 600 | 1.9 |
12:05 ET | 100 | 1.94 |
12:09 ET | 100 | 1.94 |
12:16 ET | 140 | 1.945 |
12:18 ET | 110 | 1.945 |
12:25 ET | 1000 | 1.95 |
12:27 ET | 130 | 1.945 |
12:34 ET | 100 | 1.95 |
12:41 ET | 490 | 1.945 |
12:43 ET | 110 | 1.945 |
01:01 ET | 100 | 1.97 |
01:12 ET | 100 | 1.97 |
01:32 ET | 758 | 1.95 |
01:33 ET | 1018 | 1.95 |
01:39 ET | 100 | 1.965 |
01:51 ET | 300 | 1.945 |
01:53 ET | 400 | 1.945 |
01:55 ET | 400 | 1.94 |
02:02 ET | 200 | 1.94 |
02:04 ET | 100 | 1.94 |
02:11 ET | 200 | 1.94 |
02:22 ET | 100 | 1.94 |
02:24 ET | 100 | 1.94 |
02:31 ET | 100 | 1.94 |
02:33 ET | 100 | 1.94 |
02:36 ET | 100 | 1.94 |
02:42 ET | 100 | 1.94 |
02:44 ET | 100 | 1.94 |
02:45 ET | 100 | 1.94 |
02:51 ET | 200 | 1.94 |
02:54 ET | 100 | 1.94 |
02:56 ET | 100 | 1.94 |
03:02 ET | 100 | 1.94 |
03:03 ET | 100 | 1.94 |
03:12 ET | 100 | 1.935 |
03:14 ET | 200 | 1.97 |
03:21 ET | 100 | 1.93 |
03:23 ET | 100 | 1.93 |
03:32 ET | 100 | 1.93 |
03:34 ET | 100 | 1.93 |
03:41 ET | 100 | 1.925 |
03:43 ET | 600 | 1.92 |
03:52 ET | 100 | 1.9175 |
03:54 ET | 100 | 1.925 |
03:56 ET | 200 | 1.925 |
03:59 ET | 200 | 1.92 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Rezolute Inc | 70.7M | -1.4x | --- |
Adverum Biotechnologies Inc | 71.5M | -0.5x | --- |
Provectus Biopharmaceuticals Inc | 69.2M | -17.0x | --- |
Black Diamond Therapeutics Inc | 68.9M | -0.8x | --- |
Relmada Therapeutics Inc | 68.0M | -0.4x | --- |
MyMD Pharmaceuticals Inc | 67.9M | -4.5x | --- |
Rezolute, Inc. (Rezolute) is a clinical-stage biopharmaceutical company, which is engaged in developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. The antibody modifies insulin’s binding and signaling to maintain glucose levels in a normal range, which counteracts the effects of elevated insulin in the body. It is a potential treatment for congenital hyperinsulinism (HI), which is an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase II. The Company is also developing RZ402, an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME) in Phase I.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $70.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 36.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.18 |
EPS | $-1.41 |
Book Value | $4.45 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.